Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel plus prednisone in chemotherapy-naive castration-resistant prostate cancer
NL-OMON37312Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of orteronel and prednisone in castration-resistant prostate cancer (CRPC) (6 arms), sponsored by Takeda. Primary endpoint: Serum testosterone suppression in Japan. Started Jan 2013; status: active, not recruiting.
02
Drugs
orteronelprednisone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON37312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37312.